Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
about
Hyaluronidase expression induces prostate tumor metastasis in an orthotopic mouse modelTherapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studiesCurrent approaches in treatment of triple-negative breast cancerEGF receptor trafficking: consequences for signaling and cancerIntegrated ligand-receptor bioinformatic and in vitro functional analysis identifies active TGFA/EGFR signaling loop in papillary thyroid carcinomasCetuximab for treatment of advanced squamous cell carcinoma in solid organ transplant recipients.Measuring the regulation of keratin filament network dynamics.Characterizing breast cancer xenograft epidermal growth factor receptor expression by using near-infrared optical imaging.Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer developmentPutative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patientsDermatological Side Effects of Epidermal Growth Factor Receptor Inhibitors: 'PRIDE' Complex.Vismodegib: the proof of concept in Basal cell carcinoma.Detection of cancer cells in the cerebrospinal fluid: current methods and future directions.Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer.Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutationsPhase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors.Matching the decay half-life with the biological half-life: ImmunoPET imaging with (44)Sc-labeled cetuximab Fab fragment.Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers.A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.Monoclonal antibodies and Fc fragments for treating solid tumors.Nimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model.A novel taspine analog, HMQ1611, inhibits growth of non-small cell lung cancer by inhibiting angiogenesis.A novel method to quantify IRDye800CW fluorescent antibody probes ex vivo in tissue distribution studies.Cetuximab enhanced the efficacy of chemotherapeutic agent in ABCB1/P-glycoprotein-overexpressing cancer cells.Synthetically Modified Viral Capsids as Versatile Carriers for Use in Antibody-Based Cell Targeting.Therapeutic resistance in lung cancer.Epoxyeicosatrienoic acids (EETs) regulate epithelial sodium channel activity by extracellular signal-regulated kinase 1/2 (ERK1/2)-mediated phosphorylation.Molecular mechanisms of pancreatic cancer and potential targets of treatment.Novel antibodies as anticancer agents.Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTsDesign, synthesis, and evaluation of cisplatin-containing EGFR targeting bioconjugates as potential therapeutic agents for brain tumorsTyrosine kinase inhibitors in pediatric malignancies.Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications.Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancerIntraoperative imaging in ovarian cancer: fact or fiction?HER2-siRNA delivered by EGFR-specific single chain antibody inhibits NSCLC cell proliferation and tumor growth.Cetuximab in the management of colorectal cancer.Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery.Development of active and passive human vaccines to treat methamphetamine addiction.
P2860
Q22064565-A3C524F8-DA5D-45A9-801A-4775B3A09441Q26781698-3F7E8E81-8D20-42B4-BD14-30523C029153Q26801549-6167D0C8-7606-40CC-B401-B7D88823FB43Q27021340-5EF8E661-5A2B-4B7F-B67D-78C9B85CCB56Q28475549-0717A824-F664-4C1F-872C-73202A761109Q30456764-8E71BB4D-FB54-48F2-8CFA-A4FE659B29B2Q30541008-F6719A7C-48FD-4095-90A1-9B9402E813BBQ30891321-D71CB262-C9E7-4B2E-A2BE-4456E3B1B512Q31148686-254B2822-5E97-4282-9016-61FC04A2FF55Q33621891-3E803DB6-DA52-4396-960A-D8D60A7C4A7DQ33683529-0B5691D9-8478-43D2-B639-9802EEEF3F17Q33734736-2D4AC31C-1D9C-49BA-91BF-E524DF3056DFQ33836335-3291BCBB-9373-4729-B08C-29A3CCE8DFB6Q34031229-8233B2F0-0C73-4978-99A0-B42CAE312F01Q34135471-A8CAF4F3-11AA-4F34-90CC-4CA7A8DE19E1Q34570074-3AE13756-7D13-4A3A-B609-465BC5C1CC4CQ34764397-5591A845-87F7-4FB9-A9C5-5D137AABCDCAQ35059625-916BFD75-5365-433C-96A0-F33E2473C613Q35584153-10271784-7CF5-4D63-A84A-CEFAC314B0A4Q35623965-AC823F8E-FFA9-464F-8EBB-9CC9AFAFA88AQ35699372-481D0653-1D5C-426C-8052-676421B6D760Q35955366-544A3C86-A011-4909-975C-D8655C19F471Q36403368-DE912335-CD95-464E-BDB8-7C15C4254634Q36459800-3E465C50-4A61-4AB2-8655-DB358647E8DCQ36562186-BB872765-A014-43E6-B5CE-B6C8DBD2BB8BQ36592213-FDA78F2F-09EE-4782-8432-B2D94947ECA4Q36609767-7CC42068-EAF2-4DC1-B184-BC74D3C8030FQ36620913-CC02FCAA-A102-4CA1-8628-02A635B6B58BQ36758436-F5A7CBE2-81B2-4DC7-AEE9-A0457B07161EQ36832141-1B1B69E1-9952-42A8-A5AE-B04CDE73F23CQ36853345-214EED96-B211-44D6-B7D2-EC32FDD8F50FQ36907976-5C4A5B9C-F13B-47AB-8E4E-7932A103ECECQ36977823-0C580212-2CE7-4EA0-93BE-6D8A7C1BED92Q36982489-2AA8D9B7-DFD3-49C0-B734-21B3C63F8CF6Q37132173-6207ECB2-CB67-483D-894D-DAC0A7672845Q37149571-B17EE253-9618-4633-A771-94E2C15BE2E8Q37269081-0AF9757C-AB73-445E-8278-55184FE6AAE7Q37290499-4A14AE96-94D2-44F0-B908-EBC71360B82EQ37389699-3855FFF5-69EA-44F7-A544-69DA07F3C3CEQ37411959-9BB46C3B-3A39-422C-BE43-8138EDBC9A53
P2860
Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
@ast
Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
@en
type
label
Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
@ast
Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
@en
prefLabel
Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
@ast
Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
@en
P1433
P1476
Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
@en
P2093
Barbara Burtness
Joanne Harding
P304
P356
10.1358/DOT.2005.41.2.882662
P577
2005-02-01T00:00:00Z